OTCMKTS:ARGSQ

Argos Therapeutics Stock Forecast, Price & News

$0.05
0.00 (0.00 %)
(As of 10/10/2019)
Add
Compare
Today's Range
$0.05
Now: $0.05
$0.05
50-Day Range
$0.05
MA: $0.05
$0.05
52-Week Range
$0.02
Now: $0.05
$0.25
VolumeN/A
Average Volume13,394 shs
Market Capitalization$571,698.00
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Argos Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARGSQ
CUSIPN/A
Phone919-287-6300
Employees21
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.90 million
Book Value($1.63) per share

Profitability

Miscellaneous

Market Cap$571,698.00
Next Earnings DateN/A
OptionableNot Optionable

Headlines

No headlines for this company have been tracked by MarketBeat.com

MarketRank

Overall MarketRank

0.60 out of 5 stars

Medical Sector

1379th out of 2,019 stocks

Pharmaceutical Preparations Industry

596th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.05
0.00 (0.00 %)
(As of 10/10/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive ARGSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGSQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Argos Therapeutics (OTCMKTS:ARGSQ) Frequently Asked Questions

What stocks does MarketBeat like better than Argos Therapeutics?

Wall Street analysts have given Argos Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Argos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc (OTCMKTS:ARGSQ) posted its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) EPS for the quarter, beating the Zacks' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.10 million.
View Argos Therapeutics' earnings history
.

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Argos Therapeutics shares reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the following people:
  • Dr. Charles A. Nicolette, Consultant (Age 57)
  • Mr. Jeffrey D. Abbey, Consultant & Director (Age 57)
  • Dr. Richard D. Katz, Consultant (Age 55)
  • Ms. Lori R. Harrelson CPA, CPA, VP of Fin. (Age 50)
  • Mr. William N. Wofford, Sec.

Who are some of Argos Therapeutics' key competitors?

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the OTCMKTS under the ticker symbol "ARGSQ."

How do I buy shares of Argos Therapeutics?

Shares of ARGSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Argos Therapeutics' stock price today?

One share of ARGSQ stock can currently be purchased for approximately $0.05.

How much money does Argos Therapeutics make?

Argos Therapeutics has a market capitalization of $571,698.00 and generates $1.90 million in revenue each year.

How many employees does Argos Therapeutics have?

Argos Therapeutics employs 21 workers across the globe.

What is Argos Therapeutics' official website?

The official website for Argos Therapeutics is www.argostherapeutics.com.

Where are Argos Therapeutics' headquarters?

Argos Therapeutics is headquartered at 4233 TECHNOLOGY DR, DURHAM NC, 27704.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.